Drug Similarities Provide Evidence Latitude, Temple Says; Diovan Example?
Executive Summary
Pharmacologic similarity between compounds gives FDA greater latitude in the amount and type of data required for approval, Office of Medical Policy Director Robert Temple indicated during an Aug. 3 interview with "The Pink Sheet.
You may also be interested in...
Class Effect “Moratorium” Proposed By Harvard’s Avorn; FDA Should “Grow Up”
FDA should be less reliant on potential class similarities in evaluating safety and efficacy, pharmacoepidemiologist Jerry Avorn (Harvard University) said
Class Effect “Moratorium” Proposed By Harvard’s Avorn; FDA Should “Grow Up”
FDA should be less reliant on potential class similarities in evaluating safety and efficacy, pharmacoepidemiologist Jerry Avorn (Harvard University) said
FDA Approach To Non-Inferiority Trials For Oncologics Too Rigid, Bristol Says
FDA's approach toward non-inferiority trials for cancer drugs is "excessively rigid," especially for targeted therapies and agents that seek to demonstrate improved safety, Bristol-Myers Squibb sai